Dr Alexey Tarasov, Group Leader-Nanomaterial-Based Biosensors
BioMed X GmbH
A novel electronic sensor technology platform for point-of-care diagnostics will be presented. Different nanomaterials are used to fabricate highly sensitive field-effect transistors that convert biochemical reactions into electrical signals. The sensor is versatile, low-cost, can be easily integrated into portable diagnostics devices, and offers a competitive performance compared to state-of-the-art central laboratory analyzers.
Speaker Biography (Alexey Tarasov)
Dr. Alexey Tarasov was leading the Nanomaterial-Based Biosensors group at the BioMed X Innovation Center, Heidelberg, Germany from 2015 until 2019. He received his PhD in physics from the University of Basel, Switzerland in 2012. Prior to joining BioMed X in 2015, he was a postdoctoral research fellow at the Georgia Institute of Technology, Atlanta, GA. In March 2019, he joined the University of Applied Sciences Kaiserslautern, Germany, as a Professor of Biomedical Engineering. His current research deals with electronic properties of nanomaterials with a focus on devices for biosensing applications.
Company Profile (BioMed X GmbH)
View BioMed X GmbH Timeline
The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early-career scientists recruited from all over the world work jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics and consumer care. These interdisciplinary project teams conduct outstanding biomedical research in an open-innovation lab facility on the campus of the University of Heidelberg, under the guidance of experienced mentors from academia and industry, while expanding their scientific network and receiving training in entrepreneurship and leadership. Each team is typically sponsored by a corporate pharmaceutical or biotech partner of BioMed X. At the end of a fully funded project term, successful projects are either internalized into the development pipeline of the respective pharmaceutical or biotech sponsor or spun off into an independent start-up company.